Cécile Chartier
Directeur/Membre du Conseil chez CELLECTIS S.A.
Postes actifs de Cécile Chartier
Sociétés | Poste | Début | Fin |
---|---|---|---|
CELLECTIS S.A. | Directeur/Membre du Conseil | 27/06/2023 | - |
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Directeur Technique/Scientifique/R&D | - | - |
Historique de carrière de Cécile Chartier
Formation de Cécile Chartier
Universite Louis Pasteur Strasbourg I | Doctorate Degree |
Statistiques
Internationale
France | 3 |
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 1 |
Doctorate Degree | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
Health Technology | 2 |
Technology Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
CELLECTIS S.A. | Health Technology |
Entreprise privées | 1 |
---|---|
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Technology Services |
- Bourse
- Insiders
- Cécile Chartier
- Expérience